Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · January 21, 2021

Duration of Adjuvant Doublet Chemotherapy in Patients With High-Risk Stage II Colorectal Cancer

Journal of Clinical Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Clinical Oncology
Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal Cancer
J. Clin. Oncol 2021 Jan 13;[EPub Ahead of Print], TJ Iveson, AF Sobrero, T Yoshino, I Souglakos, FS Ou, JP Meyers, Q Shi, A Grothey, MP Saunders, R Labianca, T Yamanaka, I Boukovinas, NH Hollander, F Galli, K Yamazaki, V Georgoulias, R Kerr, E Oki, S Lonardi, A Harkin, G Rosati, J Paul

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading